SeaCrest Wealth Management LLC Makes New $44,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL)

SeaCrest Wealth Management LLC acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,375 shares of the biotechnology company’s stock, valued at approximately $44,000.

A number of other large investors have also recently bought and sold shares of AVXL. DekaBank Deutsche Girozentrale grew its stake in Anavex Life Sciences by 10.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 55,000 shares of the biotechnology company’s stock worth $675,000 after buying an additional 5,000 shares in the last quarter. Liberty One Investment Management LLC grew its holdings in shares of Anavex Life Sciences by 23.3% during the 1st quarter. Liberty One Investment Management LLC now owns 13,119 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 2,479 shares during the last quarter. AllSquare Wealth Management LLC grew its holdings in shares of Anavex Life Sciences by 2.5% during the 1st quarter. AllSquare Wealth Management LLC now owns 65,956 shares of the biotechnology company’s stock valued at $812,000 after purchasing an additional 1,605 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Anavex Life Sciences by 7.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 79,840 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 5,416 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Anavex Life Sciences by 23.9% during the 1st quarter. Victory Capital Management Inc. now owns 27,997 shares of the biotechnology company’s stock valued at $240,000 after purchasing an additional 5,404 shares during the last quarter. 31.93% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Price Performance

NASDAQ:AVXL opened at $12.68 on Monday. The firm’s 50 day simple moving average is $11.17 and its 200 day simple moving average is $10.37. Anavex Life Sciences Corp. has a one year low of $7.13 and a one year high of $21.30. The company has a market cap of $988.32 million, a PE ratio of -21.49 and a beta of 0.79.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Anavex Life Sciences in a report on Wednesday, October 12th. They set a “sell” rating on the stock.

Anavex Life Sciences Company Profile

(Get Rating)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome.

Read More

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.